


D.M. KISCH INC., Johannesburg

REPUBLIC OF SOUTH AFRICA
PATENTS ACT, 1978

APPLICATION FOR A PATENT AND ACKNOWLEDGEMENT OF RECEIPT

(Section 30 (1) - Regulation 22)

The grant of a patent is hereby requested by the undermentioned applicant on the basis of the present application filed in duplicate.



Form P.1
R 20000
REPUBLIC OF SOUTH AFRICA

PATENT APPLICATION NO.		AGENT'S REFERENCE
21	01	P/94/71320
942124		

FULL NAME(S) OF APPLICANT(S)	
71	CASELLA AKTIENGESELLSCHAFT a German Company

ADDRESS(ES) OF APPLICANT(S)	
	Hanauer Landstrasse 526 D-60386 Frankfurt am Main Germany

TITLE OF INVENTION	
54	NOVEL UREA DERIVATIVES, THEIR PREPARATION AND USE
X	THE APPLICANT CLAIMS PRIORITY AS SET OUT ON THE ACCOMPANYING FORM P.2. The earliest priority claimed is DE No. P 43 09 867.3 dated 26-03-1993
	THIS APPLICATION IS FOR A PATENT OF ADDITION TO PATENT APPLICATION NO. 21 01
	THIS APPLICATION IS A FRESH APPLICATION IN TERMS OF SECTION 37 AND BASED ON APPLICATION NO. 21 01

THIS APPLICATION IS ACCOMPANIED BY :		
X	1	XXXXXXXXXXXXXXXX two copies of a complete specification of 48 pages.
	2	Drawings of sheets
X	3	Publication particulars and abstract (Form P 8. in duplicate)
	4	A copy of Figure of the drawings for the abstract
X	5	An assignment of invention
X	6	Certified priority document(s) (State number). DE NO. P 43 09 867.3
X	7	Translation of priority document(s)
	8	An assignment of priority rights.
	9	A copy of Form P 2 and specification of S A. Patent Application No 21 01
X	10	A declaration and power of attorney on Form P.3.
	11	Request for ante-dating on Form P.4.
	12	Request for classification on Form P 9.
	13	

DATED THIS 25 th DAY OF March 1994

Patent Attorney for the Applicant(s)

ADDRESS FOR SERVICE	
D.M. KISCH INC.	

RECEIVED	
OFFICIAL DATE STAMP	
1994-03-25	

Atty. Docket No. 3078/4/US
Serial No. 10/016,146
Cunningham, et al.
Reference 26

BEST AVAILABLE COPY

SN

526552921

D.M. KISCH INC. , Johannesburg

Form P.7

Patent Attorneys & Trademark Agents
Attorneys, Notaries & Conveyancers

REPUBLIC OF SOUTH AFRICA

PATENTS ACT, 1978.

COMPLETE SPECIFICATION

(Section 30 (1) - Regulation 28)

PATENT APPLICATION NO.			LODGING DATE.		AGENT'S REFERENCE
21	01	94/2124	22/23	25-03-1994	P/94/71320

INTERNATIONAL CLASSIFICATION	
51	C07K; C07C; A61K

FULL NAME(S) OF APPLICANT(S)	
71	CASELLA AKTIENGESELLSCHAFT

FULL NAME(S) OF INVENTOR(S)	
72	1. OTMAR KLINGLER; 2. GERHARD ZOLLER; 3. BERND JABLONKA 4. MELITTA JUST; 5. GERHARD BREIPOHL; 6. JOCHEN KNOLLE 7. WOLFGANG KÖNIG; 8. HANS ULRICH STILZ

TITLE OF INVENTION	
54	NOVEL UREA DERIVATIVES, THEIR PREPARATION AND USE

3541


b1874

Novel urea derivatives, their preparation and use

The present invention relates to substituted ureas and thioureas, their preparation and their use as medicines, in particular as inhibitors of blood platelet aggregation.

5 EP-A 449 079 and EP-A 530 505 describe hydantoin derivatives which have platelet aggregation-inhibiting effects. Structurally related urea derivatives are mentioned in WO-A 92 13552 and EP-A 512 829. Further investigations showed that the urea derivatives of the present invention are also
10 potent inhibitors of blood platelet aggregation.

The present invention relates to urea derivatives of the general formula I



in which


r denotes an integer from 0 to 3;

15 Z denotes oxygen or sulphur;

W denotes -COW^1 , tetrazolyl, $\text{-SO}_2\text{-OH}$ or $\text{-SO}_2\text{NHR}^9$;

W¹ denotes hydroxyl, $(\text{C}_1\text{-C}_{28})$ -alkoxy, $(\text{C}_6\text{-C}_{14})$ -aryl- $(\text{C}_1\text{-C}_8)$ -alkoxy, which can also be substituted in the aryl radical, optionally substituted $(\text{C}_6\text{-C}_{14})$ -aryloxy, amino or mono- or di- $((\text{C}_1\text{-C}_{18})$ -alkyl)amino;
20

A denotes $\text{-(CH}_2)_k\text{-NR}^a\text{-}$, in which k stands for an integer from 1 to 4, or




in which n and p independently of one another stand for an integer from 0 to 4;


25 B denotes $\text{-NR}^b\text{-(CH}_2)_m\text{-CO-}$, in which m stands for an integer from 1 to 4, or $\text{-NR}^b\text{-CHR}^s\text{-CO-}$, in which R^s denotes an amino acid side chain, or

3541


b1874



in which n stands for an integer from 0 to 4, or



5 in which s and t independently of one another can stand for an integer from 0 to 5, but the sum of s and t must be a number between 2 and 5, but where, if R stands for hydrogen, r denotes the number 1 and A stands for $-(CH_2)_k-NR^a-$, in which k stands for an integer from 2 to 4, or for



10 in which p is other than 0, then B cannot simultaneously stand for $-NR^b-(CH_2)_m-CO-$, in which m stands for the numbers 1 or 2; R^a and R^b independently of one another denote hydrogen, hydroxyl, (C_1-C_{18}) -alkyl, (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, hydroxycarbonyl- (C_1-C_6) -alkyl, (C_1-C_6) -alkoxycarbonyl- (C_1-C_6) -alkyl, (C_6-C_{14}) -aryloxycarbonyl- (C_1-C_6) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy-
15 carbonyl- (C_1-C_6) -alkyl, (C_1-C_{28}) -alkoxy, (C_6-C_{14}) -aryloxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy, (C_1-C_6) -alkylcarbonyloxy, (C_1-C_6) -alkoxy-carbonyloxy, (C_6-C_{14}) -aryloxycarbonyloxy or (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyloxy, where the aryl radicals can also be substituted;

20 R denotes hydrogen or (C_1-C_6) -alkyl;


R^1 denotes $-NH-X$ or $-C(=NX)-NH_2$;

X denotes hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy-carbonyl, which can also be substituted in the aryl radical,

3541

b1874

cyano, hydroxyl, (C_1-C_6) -alkoxy or amino or a radical of the formula II



where R' and R'' independently of one another stand for hydrogen,
5 (C_1-C_6) -alkyl, trifluoro- (C_1-C_6) -alkyl, (C_1-C_6) -alkoxycarbonyl,
 (C_1-C_6) -alkylcarbonyl, optionally substituted (C_6-C_{14}) -aryl-
carbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl,
optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl-
 (C_1-C_6) -alkoxycarbonyl, which can also be substituted in the aryl
10 radical, cyano, hydroxyl, (C_1-C_6) -alkoxy or amino;
 R^2 denotes hydrogen, (C_1-C_4) -alkyl, (C_2-C_6) -alkynyl, phenyl or a
mono- or bicyclic up to 8-membered heterocyclic ring, which can
be aromatic, partially hydrogenated or completely hydrogenated
and which can contain one, two or three identical or different
15 heteroatoms from the series nitrogen, oxygen and sulphur, where
the (C_1-C_4) -alkyl and the phenyl can be unsubstituted or mono- or
polysubstituted by identical or different radicals from the
series hydroxyl, amino, (C_1-C_4) -alkoxy, imidazolyl, indolyl,
pyrrolidinyl, hydroxypyrrolidinyl, phenyl or halogen and the
20 heterocyclic ring can be unsubstituted or mono- or poly-
substituted by identical or different radicals from the series
 (C_1-C_{18}) -alkyl, phenyl, phenyl- (C_1-C_4) -alkyl, (C_1-C_{18}) -alkoxy,
phenyl- (C_1-C_4) -alkoxy, halogen, nitro, amino, hydroxyl, trifluoro-
methyl or oxo or, in the case of nitrogen heterocycles, can be
25 present as N-oxide;
 R^3 denotes hydrogen, $-COOR^4$, $-CO-N(CH_3)R^4$ or $-CO-NH-R^4$;
 R^4 denotes hydrogen or (C_1-C_{18}) -alkyl, which can optionally be
mono- or polysubstituted by identical or different radicals from
the series hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or
30 di- $((C_1-C_{18})$ -alkyl)aminocarbonyl, amino- (C_2-C_{18}) -alkylaminocarbonyl,
amino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -
alkylcarbonylamino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl,
 (C_1-C_{18}) -alkylcarbonylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_6-C_{14}) -
aryl- (C_1-C_6) -alkoxycarbonyl, which can also be substituted in the
35 aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxy, (C_1-C_{18}) -alkoxy-

3541

b1874

carbonyl, optionally substituted (C₃-C₈)-cycloalkyl, halogen, nitro, trifluoromethyl or by the radical R⁵, where

R⁵ denotes optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring, which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the series nitrogen, oxygen and sulphur, a radical R⁶ or a radical R⁶CO-, where the aryl and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the series (C₁-C₁₈)-alkyl, (C₁-C₁₈)-alkoxy, phenyl-(C₁-C₄)-alkoxy, phenyl, phenyl-(C₁-C₄)-alkyl, halogen, nitro, amino, hydroxyl or trifluoromethyl and the heterocyclic radical can also be mono- or polysubstituted by oxo or, in the case of nitrogen heterocycles, can be present as N-oxide;

R⁶ denotes -NR⁷R⁸, -OR⁷, -SR⁷, -SO₂-OH, -SO₂-NHR⁹, tetrazolyl, an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₆-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid radical or a dipeptide radical, which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-, and also their esters and amides, where free functional groups can optionally be replaced by hydrogen or hydroxymethyl or protected by protective groups customary in peptide chemistry;

R⁷ denotes hydrogen, (C₁-C₁₈)-alkyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkoxycarbonyl, (C₆-C₁₄)-arylcarbonyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl or (C₆-C₁₄)-aryl-(C₁-C₁₈)-alkoxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted, preferably monosubstituted, by identical or different radicals from the series (C₁-C₈)-alkyl, (C₁-C₈)-alkoxy, halogen, nitro, amino and trifluoromethyl, a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₆-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid radical or a dipeptide radical, which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced

3541

b1874

to $\text{-NH-CH}_2\text{-}$;

R^8 denotes hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, which can also be substituted in the aryl radical;

5 R^9 denotes hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, (C_1-C_{18}) -alkyl or (C_3-C_8) -cycloalkyl;

and their physiologically tolerable salts.

10 Cycloalkyl radicals are in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which, however, can also be substituted, by, for example, (C_1-C_4) -alkyl. Examples of substituted cycloalkyl radicals are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.

15 Alkyl radicals can be straight-chain or branched. This also applies if they carry substituents or occur as substituents of other radicals. Examples of suitable (C_1-C_{28}) -alkyl radicals are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, decyl, undecyl, dodecyl, tridecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, docosyl, tricosyl, 20 pentacosyl, hexacosyl, heptacosyl, octacosyl, isopropyl, isobutyl, isopentyl, neopentyl, isohexyl, 3-methylpentyl, 2,3,5-trimethylhexyl, sec-butyl, tert-butyl, tert-pentyl. Preferred alkyl radicals are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

25 (C_2-C_6) -alkynyl radicals can be straight-chain or branched. Examples are ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, 1-hexynyl, 5-hexynyl or 3,3-dimethyl-1-butynyl.

30 (C_6-C_{14}) -aryl groups are, for example, phenyl, naphthyl, biphenylyl or fluorenyl, phenyl and naphthyl being preferred. The same applies to radicals such as aralkyl or arylcarbonyl. Aralkyl radicals are in particular benzyl and also 1- and 2-naphthylmethyl, which can also be substituted. Substituted aralkyl radicals are, for example, halobenzyl or (C_1-C_4) -alkoxybenzyl.

35 If phenyl is disubstituted, the substituents can be in the 1,2-, 1,3- or 1,4-position relative to one another. The 1,3- and the 1,4-positions are preferred.

Mono- or bicyclic 5- to 12-membered heterocyclic rings

and 5- to 8-membered heterocyclic rings are, for example, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl or a benza-fused or cyclopenta-, cyclohexa- or cyclohepta-fused derivative of these radicals.

These heterocycles can be aromatic or partially or completely saturated and unsubstituted or monosubstituted by identical or different radicals from the series (C₁-C₁₈)-alkyl, phenyl, phenyl-(C₁-C₄)-alkyl, (C₁-C₁₈)-alkoxy, phenyl-(C₁-C₄)-alkoxy, halogen, nitro, amino, hydroxyl, trifluoromethyl or oxo. There can be substituents on one or more nitrogen atoms and/or on one or more carbon atoms. Preferred substituents on nitrogen atoms are (C₁-C₇)-alkyl, e.g. methyl or ethyl, phenyl or phenyl-(C₁-C₄)-alkyl, e.g. benzyl, on carbon atoms (C₁-C₄)-alkyl, halogen, hydroxyl, (C₁-C₄)-alkoxy, e.g. methoxy, phenyl-(C₁-C₄)-alkoxy, e.g. benzyloxy, or oxo. Nitrogen heterocycles can also be present as N-oxides.

Radicals of this type, are, for example, 2- or 3-pyrrolyl, phenylpyrrolyl, e.g. 4- or 5-phenyl-2-pyrrolyl, 2-furyl, 2-thienyl, 4-imidazolyl, methylimidazolyl, e.g. 1-methyl-2-, 4- or 5-imidazolyl, 1,3-oxazol-2-yl, 1,3-thiazol-2-yl, 2-, 3- or 4-pyridyl, 2-, 3- or 4-pyridyl-N-oxide, 2-pyrazinyl, 2-, 4- or 5-pyrimidinyl, 2-, 3- or 5-indolyl, substituted 2-indolyl, e.g. 1-methyl-, 5-methyl-, 5-methoxy-, 5-benzyloxy-, 5-chloro- or 4,5-dimethyl-2-indolyl, 1-benzyl-2- or 3-indolyl, 4,5,6,7-tetrahydro-2-indolyl, cyclohepta[b]-5-pyrrolyl, 2-, 3- or 4-quinolyl, 1-, 3- or 4-isoquinolyl, 1-oxo-1,2-dihydro-3-isoquinolyl, 2-quinoxalinyl, 2-benzofuranyl, 2-benzothienyl, 2-benzoxazolyl or benzothiazolyl. Partially hydrogenated or completely hydrogenated heterocyclic rings are, for example, dihydropyridinyl, pyrrolidinyl, e.g. 2-, 3- or 4-(N-methylpyrrolidinyl), piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl or benzodioxolanyl.

Halogen stands for fluorine, chlorine, bromine or iodine, in particular for fluorine or chlorine.

3541


b1874

Natural and unnatural amino acids can be present, if chiral, in the D- or L-form. α -Amino acids are preferred. Examples which may be mentioned (cf. Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Volume XV/1 and 2, Stuttgart, 1974) are:

Aad, Abu, γ Abu, ABz, 2ABz, ϵ Aca, Ach, Acp, Adpd, Ahb, Aib, β Aib, Ala, β Ala, Δ Ala, Alg, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, (Cys)₂, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, Djen, Dpa, Dtc, Fel, Gln, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu, His, hIle, hLeu, hLys, hMet, hPhe, hPro, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp,

Ile, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, Lys, β Lys, Δ Lys, Met, Mim, Min, nArg, Nle, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, Δ Pro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi, β Thi, Thr Thy, Thx, Tia, Tle, Tly, Trp, Trta, Tyr, Val, Tbg, Npg, Chg, Cha, Thia, 2,2-diphenylaminoacetic acid, 2-(p-tolyl)-2-phenylaminoacetic acid, 2-(p-chlorophenyl)aminoacetic acid.

Amino acid side chains are understood as meaning side chains of natural or unnatural amino acids. Azaamino acids are natural or unnatural amino acids in which the central component





Suitable radicals of an imino acid are in particular radicals of heterocycles from the following group: pyrrolidine-2-carboxylic acid; piperidine-2-carboxylic acid; tetrahydroisoquinoline-3-carboxylic acid; decahydroisoquinoline-3-carboxylic acid; octahydroindole-2-carboxylic acid;

3541

b1874

- decahydroquinoline-2-carboxylic acid; octahydrocyclopenta[b]-pyrrole-2-carboxylic acid; 2-azabicyclo[2.2.2]octane-3-carboxylic acid; 2-azabicyclo[2.2.1]heptane-3-carboxylic acid; 2-azabicyclo[3.1.0]hexane-3-carboxylic acid; 2-azaspiro[4.4]nonane-3-carboxylic acid; 2-azaspiro[4.5]decane-3-carboxylic acid; spiro(bicyclo[2.2.1]heptane)-2,3-pyrrolidine-5-carboxylic acid; spiro(bicyclo[2.2.2]octane)-2,3-pyrrolidine-5-carboxylic acid; 2-azatricyclo[4.3.0.1.^{6,9}]decane-3-carboxylic acid; decahydrocyclohepta[b]pyrrole-2-carboxylic acid; decahydrocycloocta[c]pyrrole-2-carboxylic acid; octahydrocyclopenta[c]pyrrole-2-carboxylic acid; octahydroisoindole-1-carboxylic acid; 2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole-2-carboxylic acid; 2,3,3a,4,5,7a-hexahydroindole-2-carboxylic acid; tetrahydrothiazole-4-carboxylic acid; isoxazolidine-3-carboxylic acid; pyrazolidine-3-carboxylic acid; hydroxypyrrolidine-2-carboxylic acid; which all can be optionally substituted (see following formulae):





The heterocycles on which the abovementioned radicals are based are disclosed, for example, in

US-A 4,344,949; US-A 4,374,847; US-A 4,350,704; EP-A 29,488;
 EP-A 31,741; EP-A 46,953; EP-A 49,605; EP-A 49,658; EP-A 50,800;
 5 EP-A 51,020; EP-A 52,870; EP-A 79,022; EP-A 84,164; EP-A 89,637;
 EP-A 90,341; EP-A 90,362; EP-A 105,102; EP-A 109,020;
 EP-A 111,873; EP-A 271,865 and EP-A 344,682.

Dipeptides can contain natural or unnatural amino acids, imino acids and also azaamino acids as components. Furthermore,
 10 the natural or unnatural amino acids, imino acids, azaamino acids and dipeptides can also be present as esters or amides, such as e.g. methyl ester, ethyl ester, isopropyl ester, isobutyl ester, tert-butyl ester, benzyl ester, ethylamide, semicarbazide or ω -amino-(C₂-C₈)-alkylamide.

15 Functional groups of the amino acids, imino acids and dipeptides can be present in protected form. Suitable protective groups such as e.g. urethane protective groups, carboxyl protective groups and side chain protective groups are described in Hubbuch, Kontakte (Merck) 1979, No. 3, pages 14 to 23 and in
 20 Büllesbach, Kontakte (Merck) 1980, No. 1, pages 23 to 35. The following may be mentioned in particular: Aloc, Pyoc, Fmoc, Tcboc, Z, Boc, Ddz, Bpoc, Adoc, Msc, Moc, Z(NO₂), Z(Hal_n), Bobz, Iboc, Adpoc, Mboc, Acn, tert-butyl, OBzl, ONbz1, OMbz1, Bzl, Mob, Pic, Trt.

25 Physiologically tolerable salts of the compounds of the

3541

b1874

general formula I are in particular pharmaceutically utilizable or non-toxic salts.

Such salts are formed, for example, from compounds of the general formula I which contain acidic groups, e.g. carboxyl, with alkali metals or alkaline earth metals, such as e.g. Na, K, Mg and Ca, and also with physiologically tolerable organic amines, such as e.g. triethylamine, ethanolamine or tris(2-hydroxyethyl)amine.

Compounds of the general formula I which contain basic groups, e.g. an amino group, an amidino group or a guanidino group, form salts with inorganic acids, such as e.g. hydrochloric acid, sulphuric acid or phosphoric acid and with organic carboxylic or sulphonic acid, such as e.g. acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulphonic acid or p-toluenesulphonic acid.

The compounds of the general formula I according to the invention can contain optically active carbon atoms and can thus be present in the form of pure enantiomers or in the form of enantiomer mixtures. Both pure enantiomers and enantiomer mixtures and diastereomers and diastereomer mixtures are subjects of the present invention.


The compounds of the general formula I according to the invention can moreover contain mobile hydrogen atoms, i.e. can be present in various tautomeric forms. These tautomers are also a subject of the present invention.

Preferred compounds of the general formula I are those in which

r denotes the number 1;

W denotes $-COW^1$;

W^1 denotes hydroxyl, (C_1-C_4) -alkoxy, in particular methoxy, ethoxy, 2-propyloxy, isobutyloxy or tert-butyloxy, or benzyloxy; A denotes $-(CH_2)_k-NR^a-$, in which k stands for the numbers 1 or 2, or




3541


b1874

in which n stands for the numbers 0 or 1 and p stands for the number 0;

5 B denotes $-NR^b-(CH_2)_m-CO-$, in which m stands for the numbers 1 or 2, or $-NR^b-CHR^s-CO-$, in which R^s stands for the side chain of the amino acids alanine, valine, phenylalanine, tyrosine, leucine, isoleucine, tryptophan, lysine, histidine, asparagine, glutamine or phenylglycine, or




in which n stands for the numbers 0 or 1, or



10 in which s and t independently of one another can stand for an integer from 0 to 4, the sum of s and t, however, must give the number 3 or the number 4, where, however, if A stands for $-(CH_2)_k-NR^a-$ and k therein stands for 2, then B cannot simultaneously denote $-NR^b-(CH_2)_m-CO-$;

R denotes hydrogen;

15 X denotes hydrogen, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or a radical of the formula



20 in which R' and R'' independently of one another stand for hydrogen, trifluoroethyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl or (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl;

R^2 denotes hydrogen;

25 R^3 denotes $-CO-NH-R^4$, where $-NH-R^4$ stands for the radical of an α -amino acid, its ω -amino- (C_2-C_8) -alkylamide or its (C_1-C_8) -alkyl or benzyl ester, or where R^4 denotes methyl which is substituted


3541

b1874


by an amino acid side chain and by a radical from the series
-SO₂-OH, -SO₂-NHR⁹ and tetrazolyl.

5 Radicals of α-amino acids standing for -NH-R⁴ are in this
case particularly preferably the valine, lysine, phenylalanine,
phenylglycine or 4-chlorophenylglycine radical. If -NH-R⁴ in this
case stands for an ester of one of these α-amino acids, the
methyl, ethyl, isopropyl, isobutyl, tert-butyl ester or benzyl
ester is preferred.

10 Compounds of the formula I can be prepared by fragment
condensation of a compound of the general formula III



with a compound of the general formula IV



where the radicals A, B, W, Z, R, R¹, R² and R³ and also r are
defined as indicated above.

15 The starting compounds of the general formula IV are as a
rule synthesized stepwise from the C-terminal end. For con-
densation of the compounds of the general formula III with those
of the general formula IV, the coupling methods of peptide
chemistry known per se (see e.g. Houben-Weyl, Methoden der
Organischen Chemie [Methods of Organic Chemistry], Volumes 15/1
20 and 15/2, Stuttgart, 1974) are advantageously used. For this
coupling, it is as a rule necessary that amino groups contained
in R¹, R², R³ and W are protected by reversible protective groups
during the condensation. The same applies to the carboxyl groups
of the compounds of the formula IV, which are preferably present
25 as (C₁-C₆)-alkyl, benzyl or tert-butyl esters. Amino group
protection is unnecessary if the amino groups to be generated are
still present as nitro or cyano groups and are only formed, after
coupling, by hydrogenation. After coupling, the protective groups

3541

b1874


present are removed in a suitable manner. For example, NO₂ groups (guanidino protection), benzyloxycarbonyl groups and benzyl esters can be removed by hydrogenation. The protective groups of the tert-butyl type are cleaved by acid, while the 9-fluorenyl-methoxycarbonyl radical is removed by means of secondary amines.

The starting compounds of the general formula III can be obtained as follows:


Amine derivatives of the general formula V or amine derivatives of the general formula VI in which, as shown by way of example, the carboxylic acid group can be present as the methyl ester, where A, B and R¹



(V)




(VI)




(VII)

have the meanings indicated above, can be reacted with reactive carbonic acid derivatives of the general formula VII in which Z stands for oxygen or sulphur and the two radicals Q are identical or different leaving groups, to give the compounds of the general formula VIII or the compounds of the general formula IX



(VIII)



(IX)

Suitable leaving groups Q are, for example, halides, in particular chloride, (C₁-C₄)-alkoxy, for example methoxy, ethoxy, or isobutoxy, (C₁-C₄)-alkylthio, for example methylthio or ethylthio, unsubstituted (C₆-C₁₄)-aryloxy, in particular phenoxy, mono- or polysubstituted (C₆-C₁₄)-aryloxy, in particular substituted phenoxy, for example 4-nitrophenoxy, 4-chlorophenoxy or 2,4,5-trichlorophenoxy, or di- and triazolyl radicals, for example imidazolyl or triazolyl. Examples of reactive carbonic acid derivatives are thus phosgene, which can also be employed in the form of di- or triphosgene, thiophosgene, alkyl and aryl chloroformates, dialkyl and diaryl carbonates, in which the two

b1874


10

formula III can also be prepared using heterocumulenes:


15




or an isothiocyanate of the general formula X



20



the compounds of the general formula IIIa



25

3541

b1874


The reaction of amine derivatives of the general formula
V




in which R^1 and A have the meanings indicated above, with an isocyanato-
5 or isothiocyanatocarboxylic acid ester of the general formula XI



in which Z stands for oxygen or sulphur and Y^b stands for
- $(CH_2)_m$ -CO- or - CHR^s -CO- or



in which R^s and m and n have the meanings indicated above, leads
10 to the compounds of the general formula IIIb



or - after alkaline hydrolysis of the ester group - to the corresponding carboxylic acids.

In all reaction steps, functional groups which may be
free must be protected by suitable reversible protective groups,
15 which are later removed again in a suitable manner.

For the guanylation and nitroguanylation of the amino
compounds the following reagents can be used:

1. O-Methylisourea

(S. Weiss and H. Krommer, Chemiker Zeitung 98 (1974)
20 617-618),

2. S-Methylisothiurea

R.F. Borne, M.L. Forrester and I.W. Waters, J. Med. Chem. 20
(1977) 771-776),

3. Nitro-S-Methylisothiurea

25 (L.S. Hafner and R.E. Evans, J. Org. Chem. 24 (1959) 1157),

3541

b1874

4. Formamidinesulphonic acid

(K. Kim, Y.-T. Lin and H.S. Mosher, Tetrahedron Lett. 29 (1988) 3183-3186),

5. 3,5-Dimethyl-1-pyrazolylformamidinium nitrate

5 (F.L. Scott, D.G. O'Donovan and J. Reilly, J. Amer. Chem. Soc. 75 (1953) 4053-4054),

6. N,N'-Di-tert-butyloxycarbonyl-S-methylisothiourea

(R.J. Bergeron and J.S. McManis, J. Org. Chem. 52 (1987) 1700-1703),

10 7. N-Alkoxycarbonyl-, N,N'-dialkoxycarbonyl-, N-alkylcarbonyl- and N,N'-dialkylcarbonyl-S-methyl-isothiourea

(H. Wollweber, H. Kölling, E. Niemers, A. Widding, P. Andrews, H.-P. Schulz and H. Thomas, Arzneim. Forsch./Drug Res. 34 (1984) 531-542).

15 Amidines can be prepared from the corresponding cyano compounds by addition of alcohols (e.g. methanol or ethanol) in acidic anhydrous medium (e.g. dioxane, methanol or ethanol) and subsequent aminolysis (G. Wagner, P. Richter and Ch. Garbe, Pharmazie 29 (1974) 12-15). A further method of preparing
20 amidines is the addition of H₂S to the cyano group, followed by a methylation of the resulting thioamide and subsequent reaction with ammonia (GDR patent no. 235 866).

 The compounds of the general formula I and their physiologically tolerable salts can be administered as medicines
25 per se, in mixtures with one another or in the form of pharmaceutical preparations which permit enteral or parenteral administration and which contain as active constituent an effective dose of at least one compound of the general formula I or of an acid addition salt thereof, in addition to customary
30 pharmaceutically innocuous excipients and additives. The preparations normally contain about 0.5 to 90 % by weight of the therapeutically active compound.

 The medicines can be administered orally, e.g. in the form of pills, tablets, lacquered tablets, sugar-coated tablets,
35 granules, hard and soft gelatine capsules, solutions, syrups, emulsions or suspensions or aerosol mixtures. However, administration can also be carried out rectally, e.g. in the form

of suppositories, or parenterally, e.g. in the form of injection or infusion solutions or microcapsules, percutaneously, e.g. in the form of ointments or tinctures, or nasally, e.g. in the form of nasal sprays.

5 The pharmaceutical preparations are prepared in a manner known per se, pharmaceutically inert inorganic or organic excipients being used. For the preparation of pills, tablets, sugar-coated tablets and hard gelatine capsules, use can be made of e.g. lactose, maize starch or derivatives thereof, talc,
10 stearic acid or its salts, etc. Excipients for soft gelatine capsules and suppositories are e.g. fats, waxes, semi-solid and liquid polyols, natural or hardened oils etc. Suitable excipients for the preparation of solutions and syrups are e.g. water, sucrose, invert sugar, glucose, polyols etc. Suitable excipients
15 for the preparation of injection solutions are water, alcohols, glycerol, polyols, vegetable oils etc. Suitable excipients for microcapsules or implants are copolymers of glycolic acid and lactic acid.

 Besides the active compounds and excipients, the pharmaceutical preparations can also contain additives, such as e.g.
20 fillers, extenders, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colourants, flavourings or aromatizers, thickeners, diluents, buffering substances, and further solvents or solubilizers or
25 agents for achieving a depot effect, and also salts for changing the osmotic pressure, coating compositions or antioxidants. They can also contain two or more compounds of the general formula I or their pharmacologically acceptable acid addition salts and additionally one or more other therapeutically active substances.

30 Other therapeutically active substances of this type are, for example, circulation-promoting agents, such as dihydroergocristine, nicergoline, buphenine, nicotinic acid and its esters, pyridylcarbinol, bencyclan, cinnarizine, naftidrofuryl, raubasine and vincamine; positively inotropic compounds, such as digoxin,
35 acetyldigoxin, metildigoxin and lanatoglycosides; coronary dilators, such as carbochromen; dipyridamol, nifedipine and perhexiline; antianginal compounds, such as isosorbide dinitrate,

3541

b1874

isosorbide mononitrate, glycerol nitrate, molsidomin and verapamil; β -blockers, such as propranolol, oxprenolol, atenolol, metoprolol and penbutolol. Moreover, the compounds can also be combined, for example, with nootropically active substances, such as e.g. piracetam, or CNS-active substances, such as pirlindol, sulpiride etc.

The dose can vary within wide limits and is to be suited to the individual conditions in each individual case. In general, in the case of oral administration a daily dose of about 0.1 to 1 mg/kg, preferably 0.3 to 0.5 mg/kg, of body weight is appropriate to achieve effective results, in the case of intravenous administration, the daily dose is in general about 0.01 to 0.3 mg/kg, preferably 0.05 to 0.1 mg/kg, of body weight.

The daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, e.g. 2, 3 or 4, part administrations. If appropriate, depending on individual behaviour, it may be necessary to deviate upwards or downwards from the daily dose indicated. Pharmaceutical preparations normally contain 0.2 to 50 mg, preferably 0.5 to 10 mg, of active compound of the general formula I or of one of its pharmaceutically acceptable salts per dose.

The urea derivatives of the formula I according to the invention have the ability to inhibit the binding of fibrinogen, fibronectin and of the von Willebrand factor to integrin receptors. In this manner, they affect the cell-cell and cell-matrix interaction and can thus prevent the formation of blood platelet thrombi. Integrins are cell membrane glycoproteins and mediate cell adhesion by interaction with a plurality of extracellular proteins such as fibronectin, laminin, collagen, vitronectin, and von Willebrand factor or with other cell membrane proteins such as e.g. ICAM-1. An important receptor from the integrin family is the glycoprotein IIb/IIIa localized on blood platelets (fibrinogen receptor) - a key protein of platelet-platelet interaction and thrombus formation. A central fragment in the receptor recognition sequence of these proteins is the tripeptide Arg-Gly-Asp (E. Ruoslahti and M.D. Pierschbacher, Science 238 (1987) 491-497; D.R. Phillips, I.F. Charo,

3541

b1874

L.V. Parise and L.A. Fitzgerald, Blood 71 (1988) 831-843).

5 The urea derivatives of the general formula I therefore find an application for the prophylaxis and therapy of arterial vascular disorders such as acute myocardial infarct in combination with lysis therapy, post-infarct treatment, secondary prevention of myocardial infarct, reocclusion prophylaxis after lysis and dilatation, unstable angina pectoris, transitory ischaemic attacks, stroke, coronary bypass operation and reocclusion prophylaxis of the bypass, pulmonary embolism, 10 peripheral arterial occlusive diseases, disseminating aneurysms, for the therapy of venous and microcirculatory vascular disorders such as deep vein thrombosis, disseminated intravascular clotting, post-operative and post-partum trauma, surgical or infectious shock, septicaemia, for the therapy in disorders with 15 hyperreactive platelets, thrombotic thrombocytopenic purpura, preeclampsia, premenstrual syndrome, dialysis, extracorporeal circulation; a further application is provided in inflammations and in the treatment of tumours. Osteoporosis can further be prevented by inhibition of osteoclast binding to the bone surface. 20

The compounds are tested in particular for their inhibitory effect on blood platelet aggregation and the adhesion of fibrinogen to blood platelets. Gel-filtered blood platelets from human donor blood are used, which are activated with ADP or 25 thrombin.

The inhibition of the binding of fibrinogen to its receptor (glycoprotein IIb/IIIa) on intact, gel-filtered human platelets by the compounds according to the invention is tested. The K_i value of the inhibition of binding of ^{125}I -fibrinogen after 30 stimulation with ADP ($10\ \mu\text{M}$) is indicated. (Reference: J.S. Bennett and G. Vilaire, J. Clin. Invest. 64 (1979) 1393-1401; E. Kornecki et al., J. Biol. Chem. 256 (1981), 5695-5701; G.A. Marguerie et al., J. Biol. Chem. 254 (1979) 5357-5363; G.A. Marguerie et al., J. Biol. Chem. 255 (1980) 154-161.)

3541
b1874

In this test, the following result was obtained for the compound of the following Example 1:

Example	K_i (μ M), ADP-stimulated
1	0.03

5 As a functional test, the inhibition of the aggregation of gel-filtered human platelets is measured after ADP or thrombin stimulation by the compounds according to the invention. The IC_{50} value of the inhibition is indicated (reference: G.A. Marguerie et al., J. Biol. Chem. 254 (1979), 5357-5363).

10 In this test, the following results were obtained for the compounds of Examples 1, 6, 7, 8 and 10 below:

Example	ADP-stimulated	thrombin-stimulated
	IC_{50} (μ M)	IC_{50} (μ M)
1	0.15	0.1
6	0.75	0.3
15 7	3.0	1.5
8	2.0	2.0
10	8.5	3.0

EXAMPLES

Example 1

20 (3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl-L-phenylglycine

a) Ethyl 3-(4-cyanophenyl)ureidoacetate

25 A solution of 2.74 g (23 mmol) of 4-aminobenzonitrile in 10 ml of dimethoxyethane is added dropwise to a cooled solution (0°C) of 3 g (23 mmol) of ethyl isocyanatoacetate in 10 ml of dimethoxyethane and the mixture is stirred at room temperature. The product is filtered off and washed with dimethoxyethane.
Yield: 2.56 g (45 %)
Melting point: 142°C.

3541

b1874

b) Ethyl 3-(4-(ethoxyiminomethyl)phenyl)ureidoacetate hydrochloride

Dry HCl gas is introduced with stirring and cooling (0°C) into a suspension of 2.3 g (9.3 mmol) of ethyl 3-(4-cyanophenyl)ureidoacetate in 50 ml of anhydrous ethanol. After 30 h, the mixture is concentrated in vacuo. The residue is stirred with ether and filtered off.

Yield: 2.68 g (87 %)

Melting point: 154-157°C.

c) Ethyl 3-(4-aminoiminomethyl)phenyl)ureidoacetate hydrochloride

5.8 ml (1.5 equiv.) of ethanolic ammonia solution are added to a suspension of 2.68 g (8.1 mmol) of ethyl 3-(4-(ethoxyiminomethyl)phenyl)ureidoacetate hydrochloride in 25 ml of anhydrous ethanol. After stirring at room temperature for 5 days, the solid is filtered off and washed with ethanol.

Yield: 1.66 g (68 %).

d) Ethyl 3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)-ureidoacetate

A suspension of 1.71 g (5.7 mmol) of ethyl 3-(4-aminoiminomethyl)phenyl)ureidoacetate hydrochloride, 2.48 g (11.4 mmol) of di-tert-butyl dicarbonate and 2.86 g of sodium hydrogen carbonate in 100 ml of ethanol is heated at 50°C for 10 h. The solid is filtered off and the filtrate is concentrated in vacuo. The residue is treated with ethyl acetate and washed with water.

After drying (Na₂SO₄), it is concentrated in vacuo.

Yield: 1.64 g (79 %)

Melting point: 167-172°C.

e) Sodium 3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)-ureidoacetate

1.6 g (4.4 mmol) of ethyl 3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureidoacetate are treated with 0.18 g (4.4 mmol) of NaOH in 50 ml of ethanol and 1 ml of water. After stirring at room temperature for 20 h, the mixture is freeze-dried.

3541

b1874

Yield: 1.52 g (97 %)

MS: 359 (M+1, Na salt), 337 (M+1, acid).

f) 3-(4-(tert-Butyloxycarbonylaminoiminomethyl)phenyl)ureido-acetyl-L-Asp(OtBu)-L-phenylglycine-OtBu

5 0.5 g (1.4 mmol) of sodium 3-(4-(tert-butyloxycarbonyl-aminoiminomethyl)phenyl)ureidoacetate and 0.58 g (1.4 mmol) of L-aspartyl(OtBu)-L-phenylglycine-OtBu are dissolved in 30 ml of DMF and treated at 0°C with stirring with 0.32 g (1.5 mmol) of
10 dicyclohexylcarbodiimide, 0.19 g (1.4 mmol) of hydroxy-benzotriazole and 2 ml of ethyl morpholine. After 72 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate, the solution is washed with saturated sodium hydrogen carbonate solution and water, and the organic phase is dried and concentrated in a rotary evaporator.
15 Yield: 1.02 g (100 %).

g) (3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl-L-phenylglycine

 1.02 g (1.4 mmol) of 3-(4-(tert-butyloxycarbonylamino-iminomethyl)phenyl)ureidoacetyl-L-Asp(OtBu)-phenylglycine-OtBu
20 are treated with 1.68 g (14.6 mmol) of trifluoroacetic acid (99 %), 0.11 ml of water and 2 ml of dichloromethane and the mixture is left at room temperature for 24 h. It is concentrated in vacuo and chromatographed on Sephadex (LH-20) (butanol/glacial acetic acid/water).
25 Yield: 120 mg (15 %)
 Melting point: 194°C (dec.)
 $[\alpha]_{D20} = +27.4^{\circ}$ (c = 0.365, glacial acetic acid)
 $^1\text{H-NMR}$ (D_6 -DMSO): δ = 7.71 (d, 2H), 7.60 (d, 2H),
 7.40 - 7.20 (m, 5H), 6.74 (m, 1H); 5.08 (m, 1H),
30 4.69 (m, 1H), 3.77 (m, 2H), 2.74 - 2.60 (m, 2H),
 1.89 (s, 3H, acetic acid).

3541

b1874

Example 2

(3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-isopropyl)-L-phenylglycine isopropyl ester trifluoroacetate

a) (3-(4-(tert-Butyloxycarbonylaminoiminomethyl)phenyl)ureido)-acetyl-L-aspartyl(O-isopropyl)-L-phenylglycine isopropyl ester

1.39 g (3.87 mmol) of sodium (3-(4-(tert-butyloxy-carbonylaminoiminomethyl)phenyl)ureido)acetate and 1.50 g (3.87 mmol) of L-aspartyl(O-isopropyl)-L-phenylglycine isopropyl ester are dissolved in 30 ml of DMF and treated at 0°C with stirring with 0.88 g (4.26 mmol) of N,N'-dicyclohexyl-carbodiimide, 0.52 g (3.87 mmol) of hydroxybenzotriazole and 0.40 ml of ethylmorpholine. After 18 h, the solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo. The residue (3.92 g) is reacted further without further purification.

b) (3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-isopropyl)-L-phenylglycine isopropyl ester trifluoroacetate

3.92 g (3.87 mmol) of (3-(4-(tert-butyloxycarbonylamino-iminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-isopropyl)-L-phenylglycine isopropyl ester are treated with 3 ml of trifluoroacetic acid (99 %) and 0.3 ml of water and the mixture is stirred at room temperature for 28 h. It is freeze-dried and the residue is chromatographed on silica gel (dichloromethane/methanol 9:1, then 8:2, then dichloromethane/methanol/glacial acetic acid 9:1:1).

Yield: 730 g (29 %)

Melting point: 104°C to 109°C

MS (FAB): 570.2 [M+1]⁺

[α]_D = +5 (c = 0.6, methanol)

¹H-NMR (D₆-DMSO): δ = 9.20 (br.s, NH), 8.63 (d, NH), 8.31 (d, NH), 7.77 (d, 2H), 7.60 (d, 2H), 7.37 (m, 5H), 6.89 (t, NH), 5.31 (d, 1H), 4.86 (m, 3H), 3.76 (m, 2H), 2.74 (dd, 1H), 2.52 (dd, 1H), 1.26-1.03 (m, 12H).

3541

b1874

Example 3

(3-(4-(Methoxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester

a) Ethyl (3-(4-(methoxycarbonylaminoiminomethyl)phenyl)ureido)-acetate

5
1.74 g (22.7 mmol) of methyl chloroformate are added dropwise to a solution of 5 g (18.92 mmol) of ethyl (3-(4-(aminoiminomethyl)phenyl)ureido)acetate in 53 ml of triethylamine and 100 ml of DMF. After 7 d at room temperature, solid is filtered
10 off and the filtrate is concentrated in vacuo. The residue is chromatographed on silica gel (ethyl acetate/methanol 95:5).
Yield: 5.18 g (85 %).

b) Sodium (3-(4-(methoxycarbonylaminoiminomethyl)phenyl)ureido)-acetate

15
5.15 g (15.98 mmol) of ethyl (3-(4-(methoxycarbonylaminoiminomethyl)phenyl)ureido)acetate are dissolved in 200 ml of ethanol and treated with 7.99 ml (15.98 mmol) of a 2N NaOH and the mixture is stirred at room temperature for 24 h. It is then concentrated in vacuo and the residue is freeze-dried.
20 Yield: 4.90 g (97 %).

c) (3-(4-(Methoxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester

25
1.20 g (3.78 mmol) of sodium (3-(4-(methoxycarbonylaminoiminomethyl)phenyl)ureido)acetate and 1.98 g (3.78 mmol) of L-aspartyl(O-methyl)-L-phenylglycine methyl ester trifluoroacetate are dissolved in 40 ml of DMF and treated at 0°C with stirring with 0.86 g (4.16 mmol) of N,N'-dicyclohexylcarbodiimide, 0.51 g (3.78 mmol) of hydroxybenzotriazole and 1 ml of ethylmorpholine. After 20 h, solid is filtered off and the filtrate is
30 concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo and the residue is chromatographed on silica gel (dichloromethane/methanol 98:2, then 95:5).

3541

b1874

Yield: 780 mg (36 %)

MS (FAB): 571.9 [M+1]⁺

Melting point: 210°C to 212°C

$[\alpha]_D = +49.73^\circ$ (c = 0.9, glacial acetic acid)

5 ¹H-NMR (D₆-DMSO): δ = 9.14 (br.s, NH), 8.37 (d, NH), 7.89 (d, 2H), 7.46 (d, 2H), 7.37 (m, 5H), 6.49 (t, NH), 5.40 (d, 1H), 4.83 (m, 1H), 3.77 (m, 2H), 3.60 (s, 3H), 3.57 (s, 3H), 2.77 (dd, 1H), 2.60 (dd, 1H).

Example 4

10 (3-(4-(Benzyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester

a) Ethyl (3-(4-(benzyloxycarbonylaminoiminomethyl)phenyl)ureido)-acetate

15 0.50 g (1.66 mmol) of ethyl (3-(4-(aminoiminomethyl)-phenyl)ureido)acetate in 20 ml of THF is treated with 2.7 ml of 1N NaOH and cooled to 0°C. 0.29 ml (1.99 mmol) of benzyl chloroformate is added to this mixture and it is stirred at room temperature for 2 h. The pH is kept between 9 and 10 using 1N NaOH. The mixture is then treated with 50 ml of water and extracted
20 with ethyl acetate. After drying (MgSO₄), the solvent is removed in vacuo and the residue is stirred with ether.
Yield: 0.4 g (60 %).

b) Sodium (3-(4-(benzyloxycarbonylaminoiminomethyl)-phenyl)ureido)acetate

25 0.74 g (1.86 mmol) of ethyl (3-(4-(benzyloxycarbonylaminoiminomethyl)phenyl)ureido)acetate in 100 ml of ethanol is treated with 1.86 ml of 1N NaOH and the mixture is stirred at room temperature for 6 h. The solvent is removed in vacuo and the residue is freeze-dried.
30 Yield: 0.73 g (99 %).

3541

b1874

c) (3-(4-(Benzyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester

0.73 g (1.86 mmol) of sodium (3-(4-(benzyloxycarbonylaminoiminomethyl)phenyl)ureido)acetate and 0.61 g (1.86 mmol) of L-aspartyl(O-methyl)-L-phenylglycine methyl ester trifluoroacetate are dissolved in 40 ml of DMF and treated at 0°C with stirring with 0.42 g (2.04 mmol) of N,N'-dicyclohexylcarbodiimide and 0.25 g (1.86 mmol) of hydroxybenzotriazole. After 16 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo and the residue is chromatographed on silica gel (dichloromethane/methanol 9:1).

Yield: 304 mg (25 %)

MS (FAB): 647.8 [M+1]⁺

Melting point: 164°C to 167°C

[α]_D = +38.71 (c = 0.62; glacial acetic acid)

¹H-NMR (D₆-DMSO): δ = 9.17 (s, NH), 9.00 (br.s, 2 NH), 8.79 (d, HN), 8.39 (d, NH), 7.93 (d, 2H), 7.50 (d, 2H), 7.39 (m, 10H), 6.53 (t, NH), 5.44 (d, 1H), 5.11 (s, 1H), 4.83 (m, 1H), 3.81 (d, 2H), 3.64 (s, 3H), 3.61 (s, 3H), 2.81 (dd, 1H), 2.64 (dd, 1H).

Example 5

(3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester trifluoroacetate

a) (3-(4-(tert-Butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester

1.92 g (5.34 mmol) of sodium (3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetate are dissolved in 30 ml of DMF and treated at 0°C with stirring with 1.21 g (5.87 mmol) of N,N'-dicyclohexylcarbodiimide, 0.72 g (5.34 mmol) of hydroxybenzotriazole and 0.68 ml of ethyl morpholine. 2.18 g (5.34 mmol) of L-aspartyl(O-methyl)-L-phenylglycine methyl ester trifluoroacetate are then dissolved in 10 ml of DMF and added.

3541

b1874

After 24 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO_4), the organic phase is concentrated in vacuo.

Yield: 2.10 g (64 %).

b) (3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester trifluoroacetate

2.10 g (3.43 mmol) of (3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester are treated with 3.95 g (34.3 mmol) of trifluoroacetic acid (99 %) and 0.27 ml of water and the mixture is stirred at room temperature for 16 h. It is then concentrated in vacuo and the residue is chromatographed on silica gel (dichloromethane/methanol/glacial acetic acid 9:1:1).

Yield: 1.19 g (55 %)

MS (FAB): 513.8 $[\text{M}+1]^+$

Melting point: $>140^\circ\text{C}$

$[\alpha]_D = +9.48^\circ$ ($c = 1.06$, methanol)

$^1\text{H-NMR}$ (D_6 -DMSO): $\delta = 9.50$ (s, NH), 9.06 (br.s, 4 NH), 8.77 (d, NH), 8.37 (d, NH), 7.77 (d, 2H), 7.60 (d, 2H), 7.37 (m, 5H), 6.74 (t, NH), 5.43 (d, 1H), 4.80 (m, 1H), 3.79 (m, 2H), 3.63 (s, 3H), 3.60 (s, 3H), 2.80 (dd, 1H), 2.63 (dd, 1H).

Example 6

(3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester trifluoroacetate

a) (3-(4-(tert-Butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-tert-butyl)-L-phenylglycine methyl ester

1.00 g (2.78 mmol) of sodium (3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetate is dissolved in 30 ml of DMF and treated at 0°C with stirring with 0.63 g (3.06 mmol) of N,N'-dicyclohexylcarbodiimide and 0.38 g (2.78 mmol) of hydroxybenzotriazole. 1.04 g (2.78 mmol) of L-aspartyl(O-tert-butyl)-L-phenylglycine methyl ester

3541

b1874

hydrochloride are then dissolved in 10 ml of DMF and added. After 18 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo.

Yield: 2.01 g (100 %, still contains N,N'-dicyclohexylurea).

b) (3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl-L-phenylglycine methyl ester trifluoroacetate

2.01 g (2.78 mmol) of (3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-tert-butyl)-L-phenylglycine methyl ester are dissolved in 2.16 ml of trifluoroacetic acid (99 %) and 0.22 ml of water and the mixture is stirred at room temperature for 5 h. The solvent is removed in vacuo and the residue is chromatographed on Sephadex (LH-20) (butanol/water/glacial acetic acid).

Yield: 713 g (59 %)

MS (FAB): 499.8 [M+1]⁺

Melting point: >220°C (dec.)

[α]_D = +19.35° (c = 0.16, methanol)

¹H-NMR (D₆-DMSO): δ = 9.09 (br.s, 2 NH), 8.89 (br.s, 2 NH), 8.69 (d, NH), 8.36 (d, NH), 7.74 (d, 2H), 7.57 (d, 2H), 7.37 (m, 5H), 6.66 (t, NH), 5.40 (d, 1H), 4.74 (m, 1H), 3.77 (m, 2H), 3.66 (s, 3H), 2.71 (dd, 1H), 2.53 (dd, 1H).

Example 7

3-((3-(4-(Aminoiminomethyl)phenyl)ureido)acetylamino)-3-phenylpropionic acid

a) Benzyl 3-((3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetylamino)-3-phenylpropionate

0.20 g (0.55 mmol) of sodium (3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetate is dissolved in 20 ml of DMF and treated at 0°C with stirring with 0.12 g (0.60 mmol) of N,N'-dicyclohexylcarbodiimide and 0.07 g (0.55 mmol) of hydroxybenzotriazole. 0.14 g (0.55 mmol) of benzyl

3541

b1874

3-amino-3-phenylpropionate is then dissolved in 5 ml of DMF and added. After 24 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo. The residue (0.39 g) is reacted without further purification.

b) 3-((3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-amino)-3-phenylpropionic acid

0.38 g (0.66 mmol) of benzyl 3-((3-(4-(tert-butyloxy-carbonylaminoiminomethyl)phenyl)ureido)acetyl-amino)-3-phenylpropionate is dissolved in 30 ml of DMF and treated with 0.07 g of Pd/C (10 %). Hydrogen is then passed through for 24 h, solid is filtered off, the filtrate is concentrated in vacuo and the residue is treated with 1.53 ml of trifluoroacetic acid (99 %) and 0.15 ml of water. After stirring at room temperature for 48 h, the mixture is concentrated in vacuo and the residue is chromatographed on Sephadex (LH-20).
Yield: 28 g (11 %)
MS (FAB): 384.8 [M+1]⁺
Melting point: >134°C (dec.)
¹H-NMR (D₆-DMSO): δ = 9.20 - 8.91 (br.s, 4NH), 8.60 (d, NH), 7.71 (d, 2NH), 7.57 (d, 2H), 7.31 (m, 5H), 6.63 (t, NH), 5.20 (m, 1H), 3.74 (m, 2H), 2.66 (m, 2H).

Example 8

(3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl-benzylamide

a) (3-(4-(tert-Butyloxycarbonylaminoiminomethyl)phenyl)ureido)-acetyl-L-aspartyl(O-tert-butyl)benzylamide

0.50 g (1.39 mmol) of sodium (3-(4-(tert-butyloxy-carbonylaminoiminomethyl)phenyl)ureido)acetate is dissolved in 25 ml of DMF and treated at 0°C with stirring with 0.32 g (1.53 mmol) of N,N'-dicyclohexylcarbodiimide and 0.19 g (1.39 mmol) of hydroxybenzotriazole. 0.54 g (1.39 mmol) of

3541

b1874

L-aspartyl(O-tert-butyl)benzylamide hydrochloride is then dissolved in 5 ml of DMF and added. After 16 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO_4), the organic phase is concentrated in vacuo. Yield: 890 mg (100 %, still contains N,N'-dicyclohexylurea).

b) (3-(4-(Aminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl-benzylamide

0.89 g (1.39 mmol) of (3-(4-(tert-butyloxycarbonylaminoiminomethyl)phenyl)ureido)acetyl-L-aspartyl(O-tert-butyl)benzylamide is treated with 2.14 ml of trifluoroacetic acid (99 %) and 0.32 ml of water and the mixture is stirred at room temperature for 22 h. It is then concentrated in vacuo and the residue is chromatographed on Sephadex (LH-20).

Yield: 440 mg (72 %)

MS (FAB): 441.6 $[\text{M}+1]^+$

Melting point: 209°C to 211°C (dec.)

$[\alpha]_D = -29.57^\circ$ (c = 0.58, DMF)

$^1\text{H-NMR}$ (D_6 -DMSO): δ = 9.00 (m, 4NH), 8.40 (m, 2NH), 7.71 (d, 2H), 7.57 (d, 2H), 7.57 (d, 2H), 7.27 (m, 5H), 6.71 (t, NH), 4.29 (d, 2H), 3.80 (m, 2H), 2.70 (dd, 1H), 2.56 (dd, 1H).

Example 9

a) 3-(3-(3-(3-Aminopropyl)ureido)benzoylamino)propionic acid

a) Ethyl 3-(3-(3-(3-tert-butyloxycarbonylamino)propyl)ureido)benzoate

2.00 g (8.12 mmol) of ethyl 3-isocyanatobenzoate (78 %) are dissolved in 10 ml of DMF. A solution of 1.42 g (8.12 mmol) of 1-amino-3-tert-butyloxycarbonylamino propane in 20 ml of DMF is slowly added dropwise at 2-8°C. After stirring at room temperature for 2 h, the solvent is removed in vacuo, and the residue is treated with ethyl acetate and the mixture is washed with water. After drying (MgSO_4), solid is filtered off and the solvent is removed in vacuo. The residue is chromatographed on silica gel.

3541

b1874

Yield: 2.55 g (86 %).

b) 3-(3-(3-tert-Butyloxycarbonylaminopropyl)ureido)benzoic acid

2.50 g (6.84 mmol) of ethyl 3-(3-(3-tert-butyloxy-carbonylaminopropyl)ureido)benzoate are dissolved in 80 ml of ethanol and treated with 3.42 ml of 2N NaOH. After 7 d at room temperature, the mixture is concentrated in vacuo. The residue is treated with water, and the mixture is acidified with citric acid and extracted with ethyl acetate. After drying (MgSO₄), solid is filtered off and the solvent is removed in vacuo.

10 c) Ethyl 3-(3-(3-(3-tert-butyloxycarbonylaminopropyl)ureido)-benzoylamino)propionate

0.45 g (1.33 mmol) of 3-(3-(3-tert-butylcarbonylamino-propyl)ureido)benzoic acid is dissolved in 20 ml of DMF and treated at 0° C with stirring with 0.30 g (1.47 mmol) of N,N'-dicyclohexylcarbodiimide and 0.18 g (1.33 mmol) of hydroxybenzo-triazole. 0.21 g (1.33 mmol) of β-alanine ethyl ester hydro-chloride and 0.51 ml of N-ethylmorpholine are then dissolved in 5 ml of DMF and added. After 20 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo.

Yield: 0.65 g (100 %, still contains N,N'-dicyclohexylurea).

25 d) 3-(3-(3-(3-tert-Butyloxycarbonylaminopropyl)ureido)benzoyl-amino)propionic acid

0.61 g (1.33 mmol) of ethyl 3-(3-(3-(3-tert-butyloxy-carbonylaminopropyl)ureido)benzoylamino)propionate is dissolved in 50 ml of ethanol and treated with 0.73 ml of 2N NaOH. After 25 h at room temperature, the solvent is removed in vacuo and the residue is treated with 20 ml of water and 20 ml of ethyl acetate and acidified with citric acid. The phases are separated and the aqueous phase is extracted a further two times with 20 ml of ethyl acetate each time. After drying (MgSO₄), the solvent is removed in vacuo and the residue (0.62 g) is employed without

3541

b1874

further purification.

e) 3-(3-(3-(3-Aminopropyl)ureido)benzoylamino)propionic acid

0.62 g (1.33 mmol) of 3-(3-(3-(3-tert-butyloxycarbonyl-aminopropyl)ureido)benzoylamino)propionic acid are treated with 2 ml of trifluoroacetic acid and 0.30 ml of water and the mixture is stirred at room temperature for 19 h. The solvent is removed in vacuo and the residue is chromatographed on Sephadex (butanol/water/glacial acetic acid).

Yield: 380 mg (93 %)

MS (FAB): 309.8 [M+1]⁺

Melting point: Oil

¹H-NMR (D₆-DMSO, CF₃COOH): δ = 7.83 (m, 1H), 7.57 (m, 1H), 7.33 (m, 2H), 3.46 (m, 2H), 3.19 (m, 2H), 2.83 (m, 2H), 1.71 (m, 2H).

Example 10

3-(3-(3-Aminopropyl)ureido)benzoyl-L-aspartyl-L-phenylglycine

a) 3-(3-(3-tert-Butyloxycarbonylamino)propyl)ureido)benzoyl-L-aspartyl(O-tert-butyl)-L-phenylglycine tert-butyl ester

0.90 g (2.67 mmol) of 3-(3-(3-tert-butyloxycarbonylamino)propyl)ureido)benzoic acid is dissolved in 15 ml of DMF and treated at 0°C with stirring with 0.61 g (2.93 mmol) of N,N'-dicyclohexylcarbodiimide and 0.36 g (2.67 mmol) of hydroxybenzotriazole. 1.11 g (2.67 mmol) of L-aspartyl(O-tert-butyl)-L-phenylglycine tert-butyl ester hydrochloride and 0.34 ml of N-ethylmorpholine are then dissolved in 5 ml of DMF and added. After 17 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying (MgSO₄), the organic phase is concentrated in vacuo.

Yield: 1.82 g (98 %).

b) 3-(3-(3-Aminopropyl)ureido)benzoyl-L-aspartyl-L-phenylglycine

1.82 g (2.61 mmol) of 3-(3-(3-tert-butyloxycarbonylamino)propyl)ureido)benzoyl-L-aspartyl(O-tert-butyl)-L-phenylglycine

3541

b1874

tert-butyl ester are treated with 4 ml of trifluoroacetic acid (99 %) and 0.4 ml of water and the mixture is stirred at room temperature for 17 h. The solvent is removed in vacuo and the residue is chromatographed on Sephadex (butanol/water/glacial acetic acid).

Yield: 1.04 g (82 %)

MS (FAB): 487.2 [M+1]⁺

Melting point: >58°C

$[\alpha]_D = +27.12^\circ$ (c = 1.18, methanol)

¹H-NMR (D₆-DMSO): δ = 9.83 (s, OH), 9.61 (d, NH), 8.86 (d, NH), 7.86 (s, OH), 7.71 (br.s, 3 NH), 7.60 (d, NH), 7.34 (m, 9H), 6.46 (t, NH), 5.29 (d, 1H), 4.86 (m, 1H), 3.17 (m, 2H), 2.80 (m, 4H), 1.71 (m, 2H).

Example 11

3-(4-(Aminoiminomethyl)benzyl)-3-benzyloxyureido)acetyl-L-aspartyl-L-phenylglycine

a) 4-(Benzyloxyiminomethyl)benzonitrile

3.07 g (23.4 mmol) of 4-cyanobenzaldehyde are dissolved in 150 ml of ethanol, treated with 3.74 g (23.4 mmol) of o-benzylhydroxyamine hydrochloride and 11.7 ml of 2N NaOH and the mixture is heated to reflux for 4 h. The solvent is removed in vacuo, and the residue is treated with water and extracted with ethyl acetate. After drying (MgSO₄), the organic extract is concentrated and the residue is recrystallized from ethanol.

Yield: 3.48 g (63 %)

Melting point: 95°C.

b) 4-(Benzylaminomethyl)benzonitrile

3.44 g (15 mmol) of 4-(benzyloximinomethyl)benzonitrile in 120 ml of ethanol are cooled to -15°C. 4.46 g (48 mmol, 4.85 ml) of borane-pyridine complex are then added dropwise in the course of 10 minutes and then 26 ml of ethanolic HCl solution in the course of 20 minutes. After stirring at room temperature for 24 h, the resulting solid is filtered off, dissolved in dichloromethane and the solution is washed with water and sodium

3541

b1874

hydrogen carbonate solution. The organic phase is dried and concentrated in vacuo.

Yield: 2.73 g (76 %).

c) Ethyl (3-(4-cyanobenzyl)-3-benzyloxyureido)acetate

5 2.73 g (11 mmol) of 4-(benzyloxyaminomethyl)benzonitrile
are dissolved in 75 ml of DMF and added dropwise at 0°C to a
solution of 1.48 g of ethyl isocyanatoacetate in 75 ml of DMF.
The mixture is heated at 50°C for 3 d, then concentrated in
vacuo. The residue is taken up in ethyl acetate and the solution
10 is washed with water. The organic phase is dried (MgSO₄) and
concentrated in vacuo. The residue is dissolved in a little ethyl
acetate and precipitated with ether/petroleum ether. The
precipitate produced is reacted without further purification.
Yield: 2.99 g
15 Melting point: 82-84°C.

d) Ethyl (3-(4-(ethoxyiminomethyl)benzyl)-3-benzyloxyureido)-
acetate

2.99 g (8.14 mmol) of ethyl (3-(4-cyanobenzyl)-3-benzyl-
oxyureido)acetate are dissolved in 250 ml of ethanol and cooled
20 to -30°C. Dry HCl gas is introduced into the solution. After
24 h, excess HCl gas is driven out by nitrogen and the solvent is
removed in vacuo. The residue crystallizes from ethyl
acetate/ether.
Yield: 2.83 g (84 %)
25 Melting point: 120-122°C.

e) Ethyl (3-(4-(aminoiminomethyl)benzyl)-3-benzyloxyureido)-
acetate

2.83 g (6.84 mmol) of ethyl (3-(4-(ethoxyiminomethyl)-
benzyl)-3-benzyloxyureido)acetate are dissolved in 100 ml of
30 ethanol and treated with 6.74 ml (6.84 mmol) of ethanolic ammonia
solution. After 24 h at room temperature, the solvent is removed
in vacuo and the residue is recrystallized from ethyl
acetate/ether.
Yield: 2.34 g (89 %)

3541

b1874

Melting point: 205-208°C.

f) Ethyl (3-(4-(tert-butyloxycarbonylaminoiminomethyl)benzyl)-3-benzyloxyureido)acetate

2.30 g (5.98 mmol) of ethyl (3-(4-(aminoiminomethyl)-benzyl)-3-benzyloxyureido)acetate in 200 ml of ethanol are treated with 2.61 g (11.96 mmol) of di-tert-butyl dicarbonate and 1.50 g (17.94 mmol) of sodium hydrogen carbonate. After 2 d at 50°C, solid is filtered off and the filtrate is concentrated in vacuo.

Yield: 2.79 g (96 %)
Melting point: 86-90°C.

g) Sodium (3-(4-(tert-butyloxycarbonylaminoiminomethyl)benzyl)-3-benzyloxyureido)acetate

2.78 g (5.74 mmol) of ethyl (3-(4-(tert-butyloxy-carbonylaminoiminomethyl)benzyl)-3-benzyloxyureido)acetate in 50 ml of ethanol are treated with 0.23 g (5.74 mmol) of NaOH and 1.2 ml of water and the mixture is stirred at room temperature for 18 h. The solvent is removed in vacuo and the residue is freeze-dried.

Yield: 2.6 g (94 %)
Melting point: 129-137°C.

h) (3-(4-tert-Butyloxycarbonylaminoiminomethyl)-3-benzyloxyureido)acetyl-L-aspartyl(O-tert-butyl)-L-phenylglycine tert-butyl ester

0.5 g (1.04 mmol) of sodium (3-(4-(tert-butyloxycarbonylaminoiminomethyl)benzyl)-3-benzyloxyureido)acetate is dissolved in 20 ml of DMF and treated at 0°C with stirring with 0.24 g (1.15 mmol) of N,N'-dicyclohexylcarbodiimide and 0.14 g (1.04 mmol) of hydroxybenzotriazole. 0.43 g (1.04 mmol) of L-aspartyl(O-tert-butyl)-L-phenylglycine tert-butyl ester hydrochloride is then added. After 19 h, solid is filtered off and the filtrate is concentrated in vacuo. The residue is taken up in ethyl acetate and the solution is washed with saturated sodium hydrogen carbonate solution and water. After drying

3541

b1874

(MgSO₄), the organic phase is concentrated in vacuo and the product is reacted without further purification.

Yield: 0.93 g (still contains dicyclohexylurea).

5 i) (3-(4-(Aminoiminomethyl)benzyl)-3-benzyloxyureido)acetyl-L-aspartyl-L-phenylglycine

0.93 g (1.04 mmol) of (3-(4-(tert-butyloxycarbonylaminoiminomethyl)benzyl)-3-benzyloxyureido)acetyl-L-aspartyl(O-tert-butyl)-L-phenylglycine tert-butyl ester is treated with 1 ml of trifluoroacetic acid (99 %) and 0.1 ml of water and the mixture is stirred at room temperature for 24 h. The solvent is removed in vacuo and the residue is chromatographed on Sephadex (butanol/water/glacial acetic acid).

Yield: 0.184 g (29 %)

MS: 605 [M+1]⁺

15 Melting point: 203-210°C

¹H-NMR (D₆-DMSO): δ = 9.80 (s, 2NH), 9.40 (s, 2NH), 8.40 (d, NH), 8.10 (d, NH), 7.74 (d, 2H), 7.49 (d, 2H), 7.43-7.00 (m, 10H), 4.86 (m, 4H), 4.67 (m, 1H), 4.54 (d, 1H), 3.89 (dd, 1H), 3.63 (dd, 1H), 2.69 (dd, 1H), 2.46 (dd, 1H).

20 The following can be obtained analogously:

Example 12:

(3-(4-(Aminoiminomethyl)benzyl)ureido)acetyl-L-aspartyl-L-phenylglycine

Example 13:

25 (3-(4-(Aminoiminomethyl)phenyl)thioureido)acetyl-L-aspartyl-L-phenylglycine

Example 14:

(3-(4-(Aminoiminomethyl)benzyl)-3-hydroxyureido)acetyl-L-aspartyl-L-phenylalanine

30 Example 15:

3-(3-(2-Guanidinoethyl)ureido)benzoyl-L-aspartyl-L-valine

3541

b1874

Example 16:

1- (4- (Aminoiminomethyl) phenyl carbamoyl) pyrrolidin-2-yl-carbonyl-L-aspartyl-L-phenylglycine

Example 17:

5 4- (3- (2-Amino-2-iminoethyl) ureido) benzoyl-L-aspartyl-L-phenylglycine

Example 18:

(3- (4-Guanidinophenyl) ureido) acetyl-L-aspartyl-L-phenylglycine

Example 19:

10 2- (3- (4- (Aminoiminomethyl) phenyl) ureido) propionyl-L-aspartyl-L-phenylglycine

Example 20:

3- (3- (4- (Aminoiminomethyl) phenyl) ureido) propionyl-L-aspartyl-L-phenylglycine

15 Example 21:

((3- (4- (Aminoiminomethyl) phenyl) ureido) acetyl-L-aspartylamino-phenylmethylsulphonyl) urea

Example 22:

20 (3- (4- (Aminoiminomethyl) phenyl) -3-methylureido) acetyl-L-aspartyl-L-phenylglycine

Example 23:

(3- (4- (Aminoiminomethyl) phenyl) -1,3-dimethylureido) acetyl-L-aspartyl-L-phenylglycine.

Example 24:

25 (3- (4- (Guanidinophenyl) ureido) acetyl-L-aspartyl-L-phenylglycine

Example 25:

3- (3- (4- (Aminoiminomethyl) phenyl) ureido) acetylamino) -3- (oxazol-2-yl) propionic acid

3541

b1874

Example 26:

3-(3-(4-(Aminoiminomethyl)phenyl)ureido)acetylamino)pent-4-ynoic acid

Example 27:

5 (3-(4-(Aminoiminomethyl)phenyl)-3-benzylureido)acetyl-L-aspartyl-L-phenylglycine

Example 28:

10 (3-(4-(((1-Acetoxyethoxy)carbonyl)aminoiminomethyl)-phenyl)ureido)acetyl-L-aspartyl(O-methyl)-L-phenylglycine methyl ester

Example A

Emulsions containing 3 mg of active compound per 5 ml can be prepared according to the following recipe:

	Active compound	0.06 g
15	Neutral oil	q.s.
	Sodium carboxymethylcellulose	0.6 g
	Polyoxyethylene stearate	q.s.
	Pure glycerol	0.6 to 2 g
	Aromatizers	q.s.
20	Water	
	(demineralized or distilled)	to 100 ml

Example B

Tablets can be prepared according to the following formulation:

25	Active compound	2 mg
	Lactose	60 mg
	Maize starch	30 mg
	Soluble starch	4 mg
	Magnesium stearate	<u>4 mg</u>
30		100 mg

3541

b1874

Example C

The following composition is suitable for the preparation of soft gelatine capsules containing 5 mg of active compound per capsule:

5	Active compound	5 mg
	Mixture of triglycerides from coconut oil	<u>150 mg</u>
	Capsule contents	155 mg

Example D

10 The following formulation is suitable for the preparation of sugar coated tablets:

	Active compound	3 mg
	Maize starch	100 mg
	Lactose	55 mg
	Sec-calcium phosphate	30 mg
15	Soluble starch	3 mg
	Magnesium stearate	5 mg
	Colloidal silicic acid	<u>4 mg</u>
		200 mg

Example E

20 Sugar-coated tablets, containing an active compound according to the invention and another therapeutically active substance:

	Active compound	6 mg
	Propanolol	40 mg
25	Lactose	90 mg
	Maize starch	90 mg
	Sec-calcium phosphate	34 mg
	Soluble starch	3 mg
	Magnesium stearate	3 mg
30	Colloidal silicic acid	<u>4 mg</u>
		270 mg

3541

b1874

Example F

Sugar-coated tablets, containing an active compound according to the invention and another therapeutically active substance:

5	Active compound	5 mg
	Pirlindol	5 mg
	Lactose	60 mg
	Maize starch	90 mg
	Sec-calcium phosphate	30 mg
10	Soluble starch	3 mg
	Magnesium stearate	3 mg
	Colloidal silicic acids	<u>4 mg</u>
		200 mg

Example G

15 Capsules, containing an active compound according to the invention and another therapeutically active substance:

	Active compound	5 mg
	Nicergoline	5 mg
	Maize starch	<u>185 mg</u>
20		195 mg


Example H

Injection solutions containing 1 mg of active compound per ml can be prepared according to the following recipe:

	Active compound	1.0 mg
25	Polyethylene glycol 400	0.3 mg
	Sodium chloride	2.7 mg
	Water for injection to	1 ml

~~PATENT CLAIMS~~

1. Urea derivatives of the general formula I



in which


r denotes an integer from 0 to 3;

Z denotes oxygen or sulphur;

W denotes $-COW^1$, tetrazolyl, $-SO_2-OH$ or $-SO_2NHR^9$;


W^1 denotes hydroxyl, (C_1-C_{28}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy, which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

A denotes $-(CH_2)_k-NR^a-$, in which k stands for an integer from 1 to 4, or




in which n and p independently of one another stand for an integer from 0 to 4;

B denotes $-NR^b-(CH_2)_m-CO-$, in which m stands for an integer from 1 to 4, or $-NR^b-CH(R^s)-CO-$, in which R^s denotes an amino acid side chain, or




in which n stands for an integer from 0 to 4, or



b1874

in which s and t independently of one another can stand for an integer from 0 to 5, but the sum of s and t must be a number between 2 and 5, but where, if R stands for hydrogen, r denotes the number 1 and A stands for $-(CH_2)_k-NR^a-$, in which k stands for an integer from 2 to 4, or for



in which p is other than 0, then B cannot simultaneously stand for $-NR^b-(CH_2)_m-CO-$, in which m stands for the numbers 1 or 2; R^a and R^b independently of one another denote hydrogen, hydroxyl, (C_1-C_{18}) -alkyl, (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, hydroxycarbonyl- (C_1-C_6) -alkyl, (C_1-C_6) -alkoxycarbonyl- (C_1-C_6) -alkyl, (C_6-C_{14}) -aryloxycarbonyl- (C_1-C_6) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl- (C_1-C_6) -alkyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryloxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy, (C_1-C_6) -alkylcarbonyloxy, (C_1-C_6) -alkoxycarbonyloxy, (C_6-C_{14}) -aryloxycarbonyloxy or (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyloxy, where the aryl radicals can also be substituted;

R denotes hydrogen or (C_1-C_6) -alkyl;

R^1 denotes $-NH-X$ or $-C(=NX)-NH_2$;

X denotes hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy-carbonyl, which can also be substituted in the aryl radical, cyano, hydroxyl, (C_1-C_6) -alkoxy or amino or a radical of the formula II



(II)

where R' and R'' independently of one another stand for hydrogen, (C_1-C_6) -alkyl, trifluoro- (C_1-C_6) -alkyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkylcarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl,

b1874

optionally substituted (C_6-C_{14})-aryloxycarbonyl, (C_6-C_{14})-aryl-
(C_1-C_6)-alkoxycarbonyl, which can also be substituted in the aryl
radical, cyano, hydroxyl, (C_1-C_6)-alkoxy or amino;

R^2 denotes hydrogen, (C_1-C_4)-alkyl, (C_2-C_6)-alkynyl, phenyl or a
mono- or bicyclic up to 8-membered heterocyclic ring, which can
be aromatic, partially hydrogenated or completely hydrogenated
and which can contain one, two or three identical or different
heteroatoms from the series nitrogen, oxygen and sulphur, where
the (C_1-C_4)-alkyl and the phenyl can be unsubstituted or mono- or
polysubstituted by identical or different radicals from the
series hydroxyl, amino, (C_1-C_4)-alkoxy, imidazolyl, indolyl,
pyrrolidinyl, hydroxypyrrolidinyl, phenyl or halogen and the
heterocyclic ring can be unsubstituted or mono- or poly-
substituted by identical or different radicals from the series
(C_1-C_{18})-alkyl, phenyl, phenyl-(C_1-C_4)-alkyl, (C_1-C_{18})-alkoxy,
phenyl-(C_1-C_4)-alkoxy, halogen, nitro, amino, hydroxyl, tri-
fluoromethyl or oxo or, in the case of nitrogen heterocycles,
can be present as N-oxide;

R^3 denotes hydrogen, $-COOR^4$, $-CO-N(CH_3)R^4$ or $-CO-NH-R^4$;

R^4 denotes hydrogen or (C_1-C_{28})-alkyl, which can optionally be
mono- or polysubstituted by identical or different radicals from
the series hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or
di-((C_1-C_{18})-alkyl)aminocarbonyl, amino-(C_2-C_{18})-alkylamino-
carbonyl, amino-(C_1-C_3)-alkylphenyl-(C_1-C_3)-alkylaminocarbonyl,
(C_1-C_{18})-alkylcarbonylamino-(C_1-C_3)-alkylphenyl-(C_1-C_3)-alkylamino-
carbonyl, (C_1-C_{18})-alkylcarbonylamino-(C_2-C_{18})-alkylaminocarbonyl,
(C_6-C_{14})-aryl-(C_1-C_8)-alkoxycarbonyl, which can also be sub-
stituted in the aryl radical, amino, mercapto, (C_1-C_{18})-alkoxy,
(C_1-C_{18})-alkoxycarbonyl, optionally substituted (C_3-C_8)-
cycloalkyl, halogen, nitro, trifluoromethyl or by the radical R^5 ,
where

R^5 denotes optionally substituted (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-
(C_1-C_8)-alkyl, optionally substituted in the aryl radical, a
mono- or bicyclic 5- to 12-membered heterocyclic ring, which can
be aromatic, partially hydrogenated or completely hydrogenated
and which can contain one, two or three identical or different
heteroatoms from the series nitrogen, oxygen and sulphur, a

b1874

radical R^6 or a radical R^6CO- , where the aryl and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the series (C_1-C_{18}) -alkyl, (C_1-C_{18}) -alkoxy, phenyl- (C_1-C_4) -alkoxy, phenyl- (C_1-C_4) -alkyl, halogen, nitro, amino, hydroxyl or trifluoromethyl and the heterocyclic radical can also be mono- or polysubstituted by oxo or, in the case of nitrogen heterocycles, can be present as N-oxide;

R^6 denotes $-NR^7R^8$, $-OR^7$, $-SR^7$, $-SO_2-OH$, $-SO_2-NHR^9$, tetrazolyl, an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally N- (C_1-C_8) -alkylated or N- $((C_6-C_{14})$ -aryl- (C_1-C_8) -alkylated) azaamino acid radical or a dipeptide radical, which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to $-NH-CH_2-$, and also their esters and amides, where free functional groups can optionally be replaced by hydrogen or hydroxymethyl or protected by protective groups customary in peptide chemistry;

R^7 denotes hydrogen, (C_1-C_{18}) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_1-C_{18}) -alkylcarbonyl, (C_1-C_{18}) alkoxycarbonyl, (C_6-C_{14}) -arylcarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl or (C_6-C_{14}) -aryl- (C_1-C_{18}) -alkoxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted, preferably monosubstituted, by identical or different radicals from the series (C_1-C_8) -alkyl, (C_1-C_8) -alkoxy, halogen, nitro, amino and trifluoromethyl, a natural or unnatural amino acid, imino acid, optionally N- (C_1-C_8) -alkylated or N- $((C_6-C_{14})$ -aryl- (C_1-C_8) -alkylated) azaamino acid radical or a dipeptide radical, which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to $-NH-CH_2-$;

R^8 denotes hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, which can also be substituted in the aryl radical;

R^9 denotes hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, (C_1-C_{18}) -alkyl or (C_3-C_8) -cycloalkyl;

and their physiologically tolerable salts.

b1874


2. Urea derivatives according to Claim 1, characterized in that, in the general formula I,

r denotes the number 1;

W denotes $-COW^1$;


W^1 denotes hydroxyl, (C_1-C_4) -alkoxy, in particular methoxy, ethoxy, 2-propyloxy, isobutyloxy or tert-butyloxy, or benzyloxy;

A denotes $-(CH_2)_k-NR^a-$, in which k stands for the numbers 1 or 2, or




in which n stands for the numbers 0 or 1 and p stands for the number 0;

B denotes $-NR^b-(CH_2)_m-CO-$, in which m stands for the numbers 1 or 2, or $-NR^b-CHR^s-CO-$, in which R^s stands for the side chain of the amino acids alanine, valine, phenylalanine, tyrosine, leucine, isoleucine, tryptophan, lysine, histidine, asparagine, glutamine or phenylglycine, or



in which n stands for the numbers 0 or 1, or




in which s and t independently of one another can stand for an integer from 0 to 4, the sum of s and t, however, must give the number 3 or the number 4, where, however, if A stands for $-(CH_2)_k-NR^a-$ and k therein stands for 2, then B cannot simultaneously denote $-NR^b-(CH_2)_m-CO-$;

R denotes hydrogen;

X denotes hydrogen, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl-

b1874

(C₁-C₆)-alkoxycarbonyl or a radical of the formula



in which R' and R'' independently of one another stand for hydrogen, trifluoroethyl, (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkoxycarbonyl, (C₁-C₁₈)-alkylcarbonyloxy-(C₁-C₆)-alkoxycarbonyl or (C₆-C₁₄)-aryl-(C₁-C₆)-alkoxycarbonyl;


R² denotes hydrogen;

R³ denotes -CO-NH-R⁴, where -NH-R⁴ stands for the radical of an α-amino acid, its ω-amino-(C₂-C₈)-alkylamide or its (C₁-C₈)-alkyl or benzyl ester, or where R⁴ denotes methyl which is substituted by an amino acid side chain and by a radical from the series -SO₂-OH, -SO₂-NHR⁹ and tetrazolyl.


3. Urea derivatives according to Claim 2, characterized in that R³ denotes -CO-NH-R⁴, where -NH-R⁴ stands for the radical of the α-amino acids valine, lysine, phenylalanine, phenylglycine or 4-chlorophenylglycine, their ω-amino-(C₂-C₈)-alkylamides or their (C₁-C₈)-alkyl or benzyl esters.

4. Urea derivatives according to Claim 3, characterized in that the (C₁-C₈)-alkyl ester of the α-amino acids is the methyl, ethyl, isopropyl, isobutyl or tert-butyl ester.

5. Process for the preparation of compounds of the general formula I according to one or more of Claims 1 to 4, characterized in that a fragment condensation of a compound of the general formula III



is carried out with a compound of the general formula IV



where the radicals A, B, W, Z, R, R¹, R² and R³ and also r are

b1874

defined as indicated in Claims 1 to 4.

6. Use of a compound of the general formula I according to one or more of Claims 1 to 4 and/or of its physiologically tolerable salts as inhibitors of platelet aggregation, the metastasis of carcinoma cells, and osteoclast binding to the bone surface.

7. Pharmaceutical preparation, characterized in that it contains one or more compounds of the general formula I according to one or more of Claims 1 to 4 and/or one or more physiologically tolerable salts thereof as active compound together with pharmaceutically acceptable excipients and additives and optionally also one or more other pharmacological active compounds.

8. Process for the production of a pharmaceutical preparation, containing one or more compounds of the general formula I according to one or more of Claims 1 to 4, and/or one or more physiologically tolerable salts thereof, characterized in that these are brought into a suitable administration form together with pharmaceutically acceptable excipients and additives and optionally also one or more other pharmacological active compounds.


9. An urea derivative of the general formula I as set out in claim 1 or a physiologically tolerable salt thereof substantially as herein described with reference to the accompanying examples.

10. A process for the preparation of a compound of general formula I as set out in claim 1 or a physiologically tolerable salt thereof substantially as herein described with reference to the accompanying examples.

11. A compound of any one of claims 1 to 4 or 9 for use as an inhibitor of platelet aggregation, the metastasis of carcinoma cells, or osteoclast binding to the bone surface.

12. The use of a compound of any one of claims 1 to 4 or 9 in the preparation of a medicament for inhibiting platelet aggregation, metastasis of carcinoma cells, or osteoclast binding to the bone surface.

Dated this 25th day of March 1994



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.